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ABSTRACT
Cardiovascular disease, especially ischemic heart disease resulting from coronary artery disease (CAD), is one 
of the major causes of death and disability in the United States. Even though the dead myocardial cells can 
be replaced by scar tissue in the healing process, the resulting myocardium cannot function as well as the pre-
infarcted myocardium, because scar tissues cannot contract. This “normal” healing process results in decreased 
cardiac output, which can lead to heart failure. Moreover, the scar tissue has abnormal electrical properties, 
which can lead to sometimes fatal arrhythmias. Previous studies demonstrated that when Lac-Z-labeled healing 
cells were infused into two animal models of myocardial infarction, that these cells were found to be located 
within the myocardium, the cardiac skeleton, and the vasculature undergoing repair. These results suggested 
that healing cells have the potential to repair damaged hearts. The current series of studies were undertaken to 
determine whether healing cells customarily reside in normal non-injured hearts of small and large animals, and 
whether autologous healing cells could be infused safely into a post-myocardial infarction patient. Adult rats 
were euthanized following the guidelines of Mercer University’s IACUC. Adult pigs were euthanized following 
the guidelines of Fort Valley State University’s IACUC. The human study was performed under the guidance of 
the Medical Center of Central Georgia’s IRB. Animal hearts were harvested, fixed, cryosectioned, and stained 
with three antibodies: carcinoembryonic antigen-cell adhesion molecule-1 (CEA-CAM-1) for totipotent stem cells, 
stage-specific embryonic antigen-4 (SSEA-4) for pluripotent stem cells, and smooth muscle alpha-actin (IA4) for 
smooth muscle in the wall of the accompanying vasculature, thus serving as the positive procedural control. Cells 
positive for both CEA-CAM-1 and SSEA-4 were found to be located in adult rat and porcine hearts. Infusion of 
autologous healing cells into a post-myocardial infarcted patient resulted in an increase in their cardiac output 
after two successive healing cell infusions. Current IRB-approved studies are underway to assess the safety and 
efficacy of infused healing cells into individuals with cardiovascular disease. 
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Introduction
Cardiovascular disease, especially ischemic heart disease resulting 
from coronary artery disease (CAD), is one of the major causes of 
death and disability in the United States [1-4]. Coronary Artery 
Bypass Graft (CABG) and stenting represent current attempts to 
prevent the steadily rising number of deaths that result from acute 
myocardial infarctions (MIs) [5]. These therapies, however, present 
significant risks of their own. CABG can lead to rupture or required 
reoperation due to anastomotic stenosis. These complications raise 
the risk of this therapeutic approach. In addition, stent thrombosis 
can produce a cerebrovascular accident, leading to severe 
disability and mortality. Thus, these surgical therapies pose many 
risks, rendering them less than ideal as a therapeutic approach to 
the treatment of CAD [6]. 
Following a myocardial infarction (MI), the myocardium is often 
replaced with non-functional scar tissue [7]. Such scarring and 
damage to the myocardium often results in left ventricular systolic 
dysfunction, ventricular aneurysm, decreased cardiac output, and 
heart failure [8-10]. Thus, mortality and morbidity following a MI 
remain high despite current pharmacological treatments including 
treatment with Angiotensin Converting Enzyme Inhibitors (ACE-I) 
and/or Angiotensin-Receptor Blockers (ARBs) [9].
Since stem cells can form the functional components of heart tissue 
and cardiac blood vessels [11,12], they could also form the basis 
for therapeutic approaches that avoid the disastrous complications 
of CABG and stenting. The use of stem cells obtained from 
the human embryo is very controversial, for moral and ethical 
reasons. Moreover, the use of embryonic stem cells requires 
immunosuppressive therapy to avoid problems associated with 
HLA-mismatch and tissue rejection. Such immunosuppressive 
therapy can itself be a source of increased morbidity and mortality 
[5]. Stem cell therapy using autologous adult stem cells in place 
of embryonic stem cells would not only eliminate the moral and 
ethical controversies, but also avoid the risks of immunosuppressive 
therapy.
Previous studies noted that both totipotent and pluripotent healing 
cells were resident cell populations in the connective tissue stroma 
of skeletal muscle [13], blood [14,15], bone marrow [16], adipose 
tissue [17], dermis [17], pancreas [18], and lung [19] of adult 
mammals. Therefore, we hypothesized that similar healing cells 
may be present in adult rat and porcine hearts. The first portion 
of this study, utilizing immunocytochemical staining of sectioned 
tissues, was undertaken to address this hypothesis. The results 
demonstrated that both totipotent and pluripotent healing cells 
were located in adult rat and porcine hearts.
The second portion of this study was based on previous animal 
studies of the infusion of genomically-labeled healing cells into 
hearts of adult rat damaged to mimic myocardial infarction. These 
studies demonstrated the presence of Lac-Z-labeled cells within the 
myocardium, connective tissue cardiac skeleton, and vasculature 
tissues undergoing regeneration/repair [11,12]. Therefore, based 
on location studies in adult mammals and the animal models of 
myocardial infarction, we hypothesized that autologous healing 
cells isolated from the blood could be safely infused into a post-
myocardial infarcted patient. 
Subsequent analysis of cardiac output in this patient demonstrated 
both safety and efficacy with this technique as well. Current IRB-
approved clinical studies with a larger cohort of test subjects are 
underway to assess the safety and efficacy of infused healing cells 
into individuals with cardiovascular disease. The discovery and 
use of these totipotent and pluripotent healing cells could provide 
an important initial step toward the ultimate goal of successful and 
safe stem cell therapy for the treatment of cardiovascular disease. 
Material and Methods
Animal Studies
The use of animals in this study complied with the guidelines of 
Mercer University’s Institutional Animal Care and Use Committee 
(IACUC) and Fort Valley University’s IACUC. These guidelines 
reflect the criteria for humane animal care of the National 
Research Council as outlined in “Guide for the Care and Use 
of Laboratory Animals” prepared by the Institute of Laboratory 
Animal Resources and published by the National Institutes of 
Health (National Academy Press, 1996).
Human Studies
The use of adult humans reported herein complied with the 
guidelines of the Medical Center of Central Georgia Institutional 
Review Board. All individuals signed a consent form before 
participating in this study.
Animal Study 
Tissue Harvest – Rat
Postnatal Sprague-Dawley rats (n=10) were euthanized using 
inhalation of carbon dioxide. The anterior chest wall and abdomen 
were washed with Betadine solution and incised. Hearts were 
removed, incised through both right and left ventricles in order 
to divide the heart into upper and lower portions, and blood 
removed from the chambers with Dulbecco’s Phosphate Buffered 
Saline (Dulbecco’s Phosphate Buffered Saline (DPBS, Invitrogen, 
GIBCO, Grand Island, NY). The hearts were then placed into 
ELICA fixative.
Tissue Harvest – Pig
Twenty adult 120 lb. female Yorkshire pigs (n=20) were anesthetized 
with tiletamine and zolazepam, then prepared for surgery with a 
Betadine wash and draped in a sterile fashion. Following a mid-line 
laparotomy incision, the sternum was divided and ribs retracted. 
The pericardial sac was incised, the heart separated from the great 
vessels by a transverse incision and the heart removed into ice-
cold DPBS. The heart was divided into upper and lower portions, 
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and blood removed from the chambers with DPBS. The hearts 
were divided into pieces containing endocardium, myocardium, 
and epicardium including the overlying coronary vasculature, 
divided into approximately one-inch pieces, and placed into 
ELICA fixative.
Further Tissue Processing
The ELICA fixative consisted of aqueous 0.4% v/v glutaraldehyde, 
2% w/v paraformaldehyde, and 1% w/v glucose, Ph 7.4, with an 
osmolality 1.0 [13]. Pieces of rat and pig heart tissue were allowed 
to remain in the fixative for 1 to 24 weeks at ambient temperature. 
After fixation, the pieces of heart tissue were transferred and stored 
in Dulbecco’s Phosphate Buffered Saline (DPBS, Invitrogen, 
GIBCO, Grand Island, NY) at pH 7.4 at ambient temperature. 
Pieces of heart tissue were removed, placed into Tissue Tek OCT 
Compound 4583 (Miles Laboratory, Ames Division, Elkhart, IN) 
and then frozen at -20oC. The frozen pieces were individually 
cryostat sectioned at seven microns in thickness with a Tissue Tek 
Cryostat II (GMI, Ramsey, MN), placed on positively charged 
slides (Mercedes Medical, Sarasota, FL) and refrigerated at 
-20oC. Immunocytochemical staining was performed following 
established procedures for ELICA analysis [13,20].
Immunocytochemistry
The tissue sections were incubated with 95% ethanol to remove 
the OTC cryostat embedding medium and then washed under 
running water for five minutes. The tissue sections were incubated 
with 5.0% (w/v) sodium azide (Sigma, St. Louis, MO) in DPBS 
for 60 minutes [13]. They were then washed in running water for 
five minutes, and incubated with 30% hydrogen peroxide (Sigma, 
St. Louis, MO) for 60 minutes to irreversibly inhibit endogenous 
peroxidases [13,20]. Tissue sections were rinsed with running 
water for five minutes and incubated for 60 minutes with blocking 
agent (Vectastain ABC Reagent Kit, Vector Laboratories Inc., 
Burlingame, CA) in DPBS [13]. The blocking agent was removed 
and the sections rinsed with running water for five minutes. They 
were then incubated with primary antibody for 60 minutes. The 
primary antibodies consisted of 0.005% (v/v) carcinoembryonic 
antigen cell adhesion molecule-1 (CEA-CAM-1) in DPBS for 
totipotent stem cells [21]; 1 μg per ml of stage-specific embryonic 
antigen-4 for pluripotent stem cells (SSEA-4, Developmental 
Studies Hybridoma Bank, Iowa City, IA) in DPBS [11]; and smooth 
muscle alpha-actin (IA4, Developmental Studies Hybridoma 
Bank) in DPBS [13]. The primary antibody was removed. The 
sections were rinsed with running water for five minutes, and 
incubated with secondary antibody for 60 minutes. The secondary 
antibody consisted of 0.005% (v/v) biotinylated affinity purified, 
rat adsorbed anti-mouse immunoglobulin G (H+L) (BA-2001, 
Vector Laboratories) in DPBS [13]. The secondary antibody was 
removed. The sections were rinsed with running water for five 
minutes, and then incubated with avidin-HRP for 60 minutes. 
The avidin-HRP consisted of 10 ml of 0.1% (v/v) Tween-20 
(ChemPure, Curtain Matheson Scientific, Houston, TX) containing 
2 drops reagent-A and 2 drops reagent-B (Peroxidase Standard PK-
4000 Vectastain ABC Reagent Kit, Vector Laboratories) in DPBS 
[13]. The avidin-HRP was removed. The sections were rinsed with 
running water for five minutes, and incubated with either AEC 
or DAB substrate (Sigma) for 60 minutes. The AEC and DAB 
substrates were prepared as directed by the manufacturer. The 
substrate solution was removed. The sections were rinsed with 
running water for 10 minutes and then cover-slipped with Aqua-
mount (Vector Laboratories) [13].
Positive and negative controls were included to assure the validity 
of the immunocytochemical staining [13]. The positive controls 
consisted of adult-derived totipotent stem cells (positive for 
CEA-CAM-1) [6,15], pluripotent stem cells (positive for SSEA-
4) [5,23], and smooth muscle surrounding blood vessels within 
the tissue (positive for IA4) [15]. The negative controls consisted 
of the staining protocol with DPBS alone (no antibodies or 
substrate), without primary antibodies (CEA-CAM-1, SSEA-4, or 
IA4), without secondary antibody (biotinylated anti-mouse IgG), 
without avidin-HRP, and without substrate (AEC) [15]. 
Visual Analysis 
Stained sections were visualized using a Nikon TMS phase contrast 
microscope with bright field microscopy at 40x, 100x, and 200x. 
Photographs were taken with a Nikon CoolPix 995 digital camera. 
Human Study
Endogenous adult healing cells were isolated from blood from one 
male (n=1) who was diagnosed with a six-year history of post-
myocardial infarction with a cardiac output of 25%. In brief, adult 
human blood was obtained by venipuncture following standard 
acceptable medical practice. The blood was collected using sterile 
procedures and placed in 10-ml EDTA hemovac tubes (Beckton-
Dickinson), inverted several times to mix and then refrigerated at 
4oC for 48 hours until further processing to isolate endogenous 
stem cells within the peripheral blood plasma fraction [14,15].
Stem Cell Isolation
After 48 hours of gravity separation, the blood had separated into 
a floating plasma fraction and a sedimented cellular fraction. The 
cellular fraction contained hematopoietic stem cells, red blood 
cells, white blood cells, and most mesodermal stem cells [14,15]. 
The plasma fraction was withdrawn using a sterile pipette, placed 
in a second sterile tube and refrigerated at 4oC.
Stem Cell Identification
Totipotent stem cells are Trypan blue-positive very small spherical-
shaped cells that are less than 2.0 microns in size [14,15,21-23]. 
Transitional-totipotent stem cell/pluripotent stem cells display a 
peripheral rim that stains with Trypan blue and a central core that 
does not. They are more than 2.0 but less than 6.0 microns in size 
[14,15]. Pluripotent stem cells do not stain with Trypan blue and 
are 6.0 to 8.0 microns in size [5,13]. Germ layer lineage stem cells 
do not stain with Trypan blue and are more than 8.0 but less than 
20.0 microns in size [22,23].
Treatment 
The healing cells were segregated into two populations: totipotent 
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stem cells in the first group and pluripotent stem cells and 
mesodermal stem cells in the second group. Both groups were 
diluted in sterile 0.9% normal intravenous saline (SNS) and 
processed for intravenous infusion as a systemic delivery system 
to the heart. The totipotent stem cells were diluted in 1000-ml of 
SNS and infused over the course of two hours. The pluripotent 
stem cells and mesodermal stem cells were diluted in 250-ml of 
SNS and infused over the course of 30 min. The cardiac output was 
measured to assess heart function. This had been performed by the 
patient’s cardiologist bi-annually beginning with his myocardial 
infarction six years previously.
Results
Adult Rat
Two populations of stem cells were visualized in the heart. 
SSEA-4-positive cells were located in the visceral layer of 
serous pericardium (epicardium) of the heart, and thus outside 
of the heart (Figure 1A), whereas CEA-CAM-1-positive cells 
were located in the endomysial and perimysial connective 
tissues of the myocardium inside of the heart (Figure 1B). IA4-
positive cells containing smooth muscle alpha-actin were located 
in the tunica media of blood vessels within the heart (Figure 
1C), whereas negative controls demonstrated absence of any 
immunocytochemical staining (Figure 1D).
Figure 1: Cryosectioned and immunocytochemically stained (AEC) left 
ventricle of adult rat heart.
A: SSEA-4-positive cells (red) located within the epicardial 
connective tissues (double arrows) and within the outer portion 
of the myocardium (bracket). Intense areas of SSEA-4-positive 
cells are located surrounding blood vessels (bold arrows) along 
the outermost portion of the myocardium. Mag x100.
B: CEA-CAM-1-positive clusters of cells (red) within the inner 
portion of the myocardium (single arrows). Mag x100.
C: IA4-positive smooth muscle alpha-actin (red) within the tunica 
media of a coronary blood vessel within the outer portion of the 
myocardium (single arrow). Mag x100.
D: Absence of any positive staining, the negative procedural 
control. Mag x100.
Figure 2: Cryosectioned and immunocytochemically stained (DAB) right 
ventricle of adult rat heart.
A: SSEA-positive cells (dark cells, white arrows) along outer 
border of epicardium. Mag x200.
B: CEA-CAM-1-positive clusters of cells (dark cell clusters, black 
arrows) along interface at junction of epicardium and myocardium. 
Mag x200. 
Adult Pig
Pluripotent stem cells positive for stage-specific antigen-4 (SSEA-
4) and totipotent stem cells positive for carcinoembryonic antigen-
cell adhesion molecule-1 (CEA-CAM-1) were identified within the 
intramural myocardium of the adult porcine heart at some distance 
from the epicardium of the heart. Clusters of cells positive for 
CEA-CAM-1 were noted next to longitudinal cardiac myofibers 
(Figure 3A) and also within the connective tissues between cardiac 
myofibers (Figure 3B). Groups of cells positive for SSEA-4 were 
identified within the connective tissues between cardiac myofibers 
(Figure 3C and 3D). In addition, cells positive for CEA-CAM-1 
and SSEA-4 were also located within the connective tissue layers 
(tunica intima and tunica adventitia) of the intramural coronary 
blood vessels (Figure 3A-D).
Figure 3: Cryosectioned and immunocytochemically stained (AEC) 
porcine septal coronary arteries.
A: Clusters of cells positive for CEA-CAM-1 were noted next to 
longitudinal cardiac myofibers. Mag, x100.
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B: Clusters of cells positive for CEA-CAM-1 were noted within 
the connective tissue stroma between cardiac myofibers. Mag, 
x100.
C: Groups of cells positive for SSEA-4 were identified within the 
connective tissues between cardiac myofibers and within the wall 
structure of a coronary artery. Mag, x100.
D: Groups of cells positive for SSEA-4 were identified within the 
lumen of a coronary artery. Mag, x100.
An unexpected and apparently spontaneous repair of cardiac 
myofibers was observed within several of the adult porcine hearts. 
This apparent repair was located within cardiac myofibers of the 
interventricular septum of the adult porcine heart surrounding the 
left anterior descending (LAD) coronary artery. Clusters of CEA-
CAM-1 positive cells and SSEA-4-positive cells were located 
surrounding the left anterior descending (LAD) coronary artery 
(Figure 4A-D). However, no CEA-CAM-1-positive or SSEA-4-
positive cells were located within the lumen of the LAD or within 
the wall structure of the LAD (Figure 4A-C).
Figure 4: Cryosectioned and immunocytochemically stained (AEC) of 
spontaneous regeneration of damaged adult porcine heart muscle directly 
inferior to left anterior descending coronary artery (LAD).
A: Clusters of CEA-CAM-1-positive cells located inferior to 
LAD. Mag, x100
B: Clusters of CEA-CAM-1-positive cells located inferior to 
LAD. Mag, x200
C: Clusters of SSEA-4-positive cells located inferior to LAD. 
Mag, x200
D: Higher power image of clusters of SSEA-4-positive cells 
located inferior to LAD. Mag, x400 
Adult Human
Following a diagnosed myocardial infarction, the single patient in 
this study had a steady 25% cardiac output of six years duration 
(Figure 4). His first healing cell infusion consisted of a slow infusion 
with autologous totipotent stem cells followed a quicker infusion 
of pluripotent stem cells and mesodermal stem cells. Six months 
following his first cell infusion his cardiac output rose to 35% 
(Figure 4), a 40% increase in cardiac output. He was transfused 
with autologous healing cells a second time following the same 
protocol as his first infusion, i.e., slow infusion with totipotent 
stem cells followed by a quicker infusion with pluripotent stem 
cells and mesodermal stem cells. Six months following his second 
cell infusion his cardiac output had risen to 45% (Figure 5), an 
additional increase of approximately 28%. 
Figure 5: Histogram of cardiac output in a patient (n=1) suffering from 
a myocardial infarction of six years duration before initial healing cell 
transplant. From the time of myocardial infarction to first autologous 
stem cell infusion his cardiac output was 25%, measured bi-annually by 
his cardiologist. At his bi-annual check-up six months after his first stem 
cell transplant his cardiac output had risen to 35%. He was transplanted a 
second time. Six months following his second transplant, at his bi-annual 
check-up, his cardiac output had risen to 45%.
Discussion 
Cardiac disease and its consequences
For decades, the broad class of cardiovascular diseases (CVD) 
has been the leading cause of mortality worldwide, responsible 
for 30% of all deaths (about 17 million annually). CVD is 
responsible for more than 7.5 million inpatient cardiovascular 
(CV) procedures in the US. CVD places a significant economic 
burden on patients and health care systems. In 2010, the direct 
medical costs of CVD totaled US $272 billion in the US alone 
(2008 USD). In the European Union (EU), direct medical costs 
of CVD are estimated to reach €106 billion annually. The health 
care burden of CVD continues to grow with an aging population 
as well as the contribution of clinical risk factors, such as obesity, 
high-lipid levels, and consequent atherosclerosis and hypertension 
[3]. Heart disease, including myocardial infarction, represents 
an enormous burden on the health care systems of the developed 
world. However, the incidence of increase of myocardial infarction 
and other cardiac diseases is also rising sharply in the less well- 
developed areas of the third world [1,2].
Myocardial infarction and the consequent loss of fully functional 
myocardium is a major factor in the etiology of heart failure [24]. 
Heart failure is a common, disabling, and lethal condition [4,25]. 
The prognosis of patients with heart failure is poor, with a failure 
rate approaching 50%. The loss of cardiac tissue underlies heart 
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failure, but current treatments do not address this problem.
Once the myocardium dies in a myocardial infarction, it is replaced 
by scar tissue over several weeks. The size, location, composition, 
structure and mechanical properties of the healing scar are all 
critical determinants of the fate of patients who survive the initial 
infarction [7]. An additional complication is that scar tissue can 
disrupt the electrical properties of the myocardium, predisposing 
the patient to arrhythmias, which can prove to be fatal. Ventricular 
arrhythmias are particular likely to require cardioversion in order 
to prevent fatal events [10]. Such scarring and damage to the 
myocardium often results in left ventricular systolic dysfunction, 
ventricular aneurysm, and heart failure [8-10]. Thus, mortality 
and morbidity following myocardial infarction remain high 
despite current pharmacological treatments including treatment 
with Angiotensin Converting Enzyme Inhibitors (ACE-I) and/or 
Angiotensin-Receptor Blockers (ARBs) [9].
Functional Cells, Healing Cells, and Maintenance Cells
There are three basic categories of cells within animals, i.e., 
functional cells, maintenance cells, and healing cells. The 
functional cells comprise the majority of the cell types and are 
composed of both stroma and parenchyma [26]. A few examples 
are of functional cells are adipocytes, fibrocytes, and cardiac 
myocytes. Maintenance cells support the functional cells on a 
daily basis by replacing functional cells as they wear out and die 
as well as providing trophic factors for their function and survival. 
Examples of maintenance cells include adipoblasts, fibroblasts, 
myoblasts, mesenchymal stem cells, medicinal secreting cells, and 
progenitor cells [26-31]. 
Healing cells are normally dormant and can be found hibernating 
within the stromal connective tissues of the body [16,32]. Their 
function in replacing functional cells and maintenance cells that 
have been lost due to trauma and/or disease. Examples of healing 
cells are totipotent stem cells [16,21,26,31], pluripotent stem cells 
[11,14,26,31,33], ectodermal stem cells [26,31], mesodermal stem 
cells [26,31,34], and endodermal stem cells [26,31]. Healing cells 
comprise approximately 10% of all the cells of the body and are 
ubiquitous throughout all organs and tissues of the body. More 
specifically, totipotent stem cells comprise approximately 0.1%, 
pluripotent stem cells approximately 0.9%, and the ectodermal 
stem cells, mesodermal stem cells, and endodermal stem cells 
approximately 9% of all cells of the body [12,26,31].
Previous studies by Young and colleagues demonstrated the 
isolation, repetitive single cell serial dilution clonogenic analysis, 
characterization, and genomic labelling with Lac-Z (beta-
Galactosidase) of 58 clones of rat healing cells. These clones 
consisted of totipotent stem cells, transitional-totipotent stem cell/
pluripotent stem cells, pluripotent stem cells, germ layer lineage 
stem cells, ectodermal stem cells, mesodermal stem cells, and 
endodermal stem cells [11,12,21]. Totipotent stem cells have the 
capability of forming all cell types of the body, including the 
germ cells, sperm and ova [21]. Pluripotent stem cells (i.e., cells 
designated as transitional-totipotent stem cell/pluripotent stem 
cells, pluripotent stem cells, and germ layer lineage stem cells) 
can form any cell type of the body, but cannot form the germ cells, 
sperm and ova [11,12]. Ectodermal stem cells can form any cell 
type of the embryonic ectodermal germ layer lineage [12,35]. 
Mesodermal stem cells can form any cell type of the embryonic 
mesodermal germ layer lineage [12,35]. And endodermal stem 
cells can form any cell type of the embryonic endodermal stem 
cell lineage [12,35]. 
Subsequent studies, utilizing a transitional-totipotent stem 
cell/pluripotent stem cell clone, designated as Scl-40β, and a 
totipotent stem cell clone, designated as Scl-44β, were utilized to 
encase allogeneic islets to form a pancreatic islet organoid as a 
proposed treatment modality for Type-I diabetes [18]. Scl-40β also 
demonstrated its ability to incorporate into and replace damaged 
cells and tissues in a Parkinson’s disease model [36,37] and in two 
animal models of myocardial infarction [11,12]. One myocardial 
infarction model consisted of freezing the apex of the heart, while 
the other model consisted of transiently ligating the left anterior 
descending coronary artery. In both instances, genomically-labeled 
cells could be found in the regenerating myocardium, regenerating 
cardiac skeleton, and regenerating vasculature [11,12].
The genomically-labeled clones of healing cells were derived 
from the connective tissues of skeletal muscle from outbred 
Sprague-Dawley. Stout et al. [38] demonstrated that with trauma, 
connective tissue resident healing cells within the skeletal muscle 
would migrate into the vasculature and home to the site of 
damage, whether that site was skeletal muscle or not. These results 
suggested the possibility that similar types of stem cells resident in 
one tissue would affect repair in a second dissimilar tissue. 
These results also suggested that similar types of healing cells, i.e., 
totipotent stem cells, pluripotent stem cells, were located in various 
tissues and organs throughout the body. Young and colleagues have 
been addressing that issue with normal uninjured adult rat tissues 
and organs utilizing cryosectioning and staining with antibodies 
unique for totipotent stem cells and pluripotent stem cells. Thus 
far, they have noted that totipotent healing cells and pluripotent 
healing cells exist within skeletal muscle [13], blood [14,15], bone 
marrow [16], adipose tissue [17], dermis [17], pancreas [18], and 
lung [19] of adult animals. Due to the lack of ability of the heart to 
heal itself, the current study addressed whether healing totipotent 
cells and pluripotent cells were natural residents within the heart.
 
Young et. al. have previously reported the presence of primitive 
pluripotent epiblast-like stem cells (positive for SSEA-4) and 
primitive totipotent blastomere-like stem cells (positive for 
CEA-CAM-1) in a variety of species of post-natal mammals 
[13-19]. Recent research by Stout et al. [38] in the adult pig has 
demonstrated that primitive pluripotent stem cells exist not only 
in the peripheral blood but also as a resident population of stem 
cells located within the skeletal muscle. They also demonstrated 
an increase in the number of primitive pluripotent stem cells 
passing into the peripheral blood from the skeletal muscle after 
only 90 minutes of trauma. Since native pluripotent stem cells are 
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located both in the blood and in the skeletal muscle of adult pigs 
[38], we hypothesized that similar native primitive pluripotent 
stem cells may be present in the adult porcine heart where they 
may contribute in some fashion to myocardial repair. The results 
demonstrate that populations of cells positive for CEA-CAM-1 or 
SSEA-4 were located within the connective tissues (endomysium 
and perimysium) between the intramural myocardial fibers as well 
as within the connective tissue layers (tunica intima and tunica 
adventitia) of the intramural coronary vessels. Their presence 
within the intramural tissues of the adult porcine heart suggests a 
role in the normal maintenance and repair of damaged or senescent 
tissues. The possibility exists that these endogenous primitive 
pluripotent stem cells could assist in the repair of damaged 
myocardium following a myocardial infarction, although further 
research will be required to examine this hypothesis. 
Regeneration of the patient’s own blood vessels could permit the 
replacement of the patient’s own stenotic coronary artery with 
an autologous clone of the artery. Such advanced regenerative 
therapy could eliminate some of the risks associated with current 
therapeutic approaches to the treatment of coronary artery disease 
and myocardial infarction. The use of autologous adult stem cells 
provides promise in the treatment of patients who have suffered 
a myocardial infarction, as well as those in the earlier stages of 
CAD. 
Some reports concerning the use of stem cells to attempt to repair 
the myocardium have appeared [25,40,41]. This work is in its 
infancy, and often has revolved around the use of mesenchymal 
stem cells. There is data indicating that more primitive cells 
such as very small, embryonic-like (VSEL) stem cells are more 
effective in the treatment of lesions than the more differentiated 
mesenchymal stem cells, at least in the lung [42]. The issue of 
which cells are most effective in healing the tissues of the body 
such as the myocardium, will certainly require much further study.
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